| DC66293 |
DSPE-PEG-N3
Featured
|
DSPE-PEG-N3 is a click chemical PEG reagent. Azide group is easy to react with alkynyl group under the catalysis of copper catalyst. It can also react directly with DBCO without any catalyst. DSPE (1,2-distearoyl-sn-glycerol-3-phosphoethanolamine) is a saturated 18 carbon phospholipid, which is commonly used in the synthesis of liposomes. Polyethylene glycol (PEG) - coupled DSPE is hydrophilic and can be used for drug delivery, gene transfection and biomolecular modification. The PEG of phospholipid significantly improved the blood circulation time and stability of the capsule drug. Polyethylene glycol can enhance the solubility and stability, reduce the non-specific binding of charged molecules on the surface, and reduce the immunogenicity of polypeptides.
Azide (- N3) can react with copper catalyzed alkynes in aqueous solution and be reduced to amino groups. Polyethylene glycol can increase solubility and stability. It can also inhibit the nonspecific binding of charged molecules on the modified surface.
|
|
| DC66294 |
DSPE-PEG-NBD
Featured
|
DSPE-PEG-NBD is a fluorescent phospholipid PEG conjugate, which can be used as a lipid membrane probe. The excitation/emission wavelength of NBD is 460 nm/534 nm. |
|
| DC66295 |
DSPE-PEG-CY7
Featured
|
Polyethylene glycol phospholipid is an excellent material to form liposomes, which can be used for gene transfection, vaccine delivery, drug transportation, and targeted drug delivery. Phospholipids are hydrophobic and hydrophilic. It can be used to modify protein drugs, peptide compounds, organic small molecule drugs, biological materials, etc. Cy7 labeled PEG derivatives are used for fluorescence tracing or fluorescence observation. |
|
| DC66296 |
DSPE-PEG-alkyne (MW 2000)
Featured
|
The phospholipid polyethylene glycol alkyne (DSPE PEG Alkyne) can be used to modify proteins, peptides and other materials or small molecules. Alkynyl (- ALK) can react with copper catalyzed azide in aqueous solution. 2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) conjugated polyethylene glycol is a combination of phospholipid and polyethylene glycol with hydrophilicity and hydrophobicity. Polyethylene glycol phospholipid liposomes form high-quality materials, which can be used for drug delivery, gene transfection and vaccine delivery. PEGylated phospholipid can significantly improve blood circulation time and stabilize drug encapsulation. These materials can also be used for targeted drug delivery by modifying ligands with target surfaces such as antibodies and peptides. |
|
| DC66297 |
DSPE
Featured
|
DSPE is a phosphoethanolamine (PE) lipid that can be used in the synthesis of liposomes. |
|
| DC66298 |
DSPE-PEG-Cy5(MW 2000 )
Featured
|
The molecules can be labeled in the aqueous phase without organic solvents. Therefore, the product is especially suitable for labeling proteins that are easily denatured in the organic phase and proteins with low solubility.
Polyethylene glycol phospholipid liposomes form high-quality materials, which can be used for drug delivery, gene transfection and vaccine delivery. Pegylated phospholipids can significantly improve blood circulation time and stabilize drug encapsulation. These materials can also be used for targeted drug delivery by modifying surface ligands such as antibodies and peptides. (DSPE) conjugated polyethylene glycol is a combination of phospholipids and polyethylene glycol, which has hydrophilicity and hydrophobicity. These materials can also be used for targeted drug delivery by modifying ligands with target surfaces, such as antibodies and peptides.
Cyanogen dye cyanine is often used in biomolecular labeling, fluorescence imaging and other fluorescent biological analysis. Cy5 (sulfo-cyanine5) is a reactive dye used to label amino groups of peptides, proteins and oligonucleotides. Excitation wavelength (nm): 649, emission wavelength (nm): 670. |
|
| DC66299 |
DSPE-PEG-Cy5.5
Featured
|
DSPE-PEG-Cy5.5is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. "&B26&"can be used in drug delivery research." |
|
| DC66300 |
ZM-306416 HCI
Featured
|
|
|
| DC66301 |
WHI-P97 HCl
Featured
|
|
|
| DC66302 |
PKC-theta inhibitor hcl
Featured
|
PKCθ inhibitor is an inhibitor of PKCθ. |
|
| DC66303 |
STING-IN-3
Featured
|
STING-IN-3 is an inhibitor of stimulator of interferon genes (STING). STING-IN-3 efficiently inhibits both hsSTING and mmSTING through covalently target the predicted transmembrane cysteine residue 91 and thereby block the activation-induced palmitoylation of STING. |
|
| AES-350 |
AES-350
Featured
|
AES-350 is a potent and orally active HDAC6 inhibitor with an IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC50 values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research. |
|
| DC66305 |
WAY-328133
Featured
|
useful for the treatment of cystic fibrosis |
|
| DC66306 |
WAY-328182
Featured
|
restore E-cadherin expression in the SW620 colon adenocarcinoma cell line |
|
| DC66307 |
WAY-328168
Featured
|
antagonist of the NK3 receptor; altering the lifespan of a eukaryotic organism; |
|
| DC66308 |
WAY-299775
Featured
|
potential leads for chaperone therapy for Gaucher disease |
|
| DC66309 |
NFATc1-IN-1
Featured
|
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research. |
|
| DC66310 |
WAY-388798
Featured
|
|
|
| DC66311 |
BRD4 Inhibitor-24
Featured
|
BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively. |
|
| DC66312 |
DB2313 HCl
Featured
|
DB2313 is a first-in-class potent small-molecule inhibitor of PU.1. DB2313 disrupts the interaction of PU.1 with target gene promoters and leads to down-regulation of canonical PU.1 transcriptional targets. |
|
| DC66313 |
WAY-301158
Featured
|
antitubercular activity; fungicidal activity; |
|
| DC66314 |
WAY-310301
Featured
|
anti-inflammatory, COX inhibitory activities and ulcerogenic liability |
|
| DC66315 |
WAY-326101
Featured
|
glucocerebrosidase activator; |
.gif)
|
| DC66316 |
BMS-P5 HCl
Featured
|
BMS-P5 is a Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma. |
|
| DC66318 |
WAY-301522
Featured
|
|
|
| DC66319 |
WYE-176249
Featured
|
VEGF inhibitor |
|
| DC66320 |
WAY-301122
Featured
|
cytotoxity (targeted to DNA topoisomerase II); anti-cancer activity; fungicides; |
|
| DC66321 |
WAY-328141
Featured
|
useful for the treatment of cystic fibrosis; modulating CFTR activity; altering the lifespan of a eukaryotic organism; |
|
| DC66322 |
WAY-327512
Featured
|
activate TLR8-dependent NF-kB signaling |
|
| DC66323 |
WAY-270252
Featured
|
IGF-1R/SRC inhibitor |
|
